Novartis AG (NVS) Stock Price & How to Invest

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

The defining story in 2026 is a large patent cliff. Entresto, its heart-failure drug and top seller at around $7.75 billion in 2025, began facing generic competition, with first-quarter 2026 sales down about 42% year over year, and Tasigna and Promacta/Revolade also losing exclusivity. To offset this, Novartis leans on five priority growth brands that collectively surged in 2025 and 2026: Kisqali (breast cancer), Kesimpta (multiple sclerosis), Pluvicto (a radioligand prostate-cancer therapy), Leqvio (cholesterol), and Scemblix (leukemia). It has also added to its pipeline through deals, including the roughly $12 billion acquisition of Avidity Biosciences for late-stage neuromuscular RNA therapies completed in early 2026. Management guided full-year 2026 to low single-digit sales growth with a low single-digit decline in core operating income, reflecting the near-term drag from generics and R&D investment.

The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off. Large acquisitions such as Avidity add integration and financing risk and raised net debt. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.

10 analysts publish price targets on NVS, averaging $155.37 against a $156.15 price as of August 2026, or -0.5%. The published targets run from $123.00 to $180.00, a moderate spread, and the ratings split 5 buy, 4 hold, 3 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NVS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Novartis AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Priority growth brands offsetting the cliff. Novartis is counting on five priority brands to replace lost Entresto revenue. The most optimistic published target, $180.00, assumes this works close to its best case.

The case against. The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. The most pessimistic target, $123.00, is roughly what NVS is worth if this bites instead.

Read the full bull and bear case on NVS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Novartis AG's investor relations page or your broker.

• Revenue (TTM): Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion
• Growth drivers: Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline
• Margins/profitability: High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure
• Dividend: Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders
• Market cap: Large-cap, broadly in the range of a couple hundred billion dollars; verify the live figure
• Analyst view: Generally constructive, with recent ratings including Buy calls; sentiment hinges on whether growth brands outrun the patent cliff

Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

If you want NVS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to NVS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NVS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (VEA, IXUS, VGK), which spreads the position across many companies. Or build it into a focused thematic portfolio, so NVS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NVS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Novartis is a focused, high-margin innovative-medicines company whose newer growth brands are racing to offset the loss of exclusivity on older blockbusters. It suits investors who want defensive pharma exposure with a dividend, provided they accept patent-cliff and pipeline risk.

Whether NVS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVS a buy or a sell?, and where the stock could go from here in the NVS stock forecast.

For income investors, whether NVS pays a dividend and how the payout looks is covered in does NVS pay a dividend? And to weigh NVS against a peer, read the full side-by-side comparisons: NVS vs PFE and NVS vs AZN.